AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1280802 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg ibuprofen
Number of subjects: 26
Study 1280802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 3894278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 0
Study 3894278 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 0
Study 31399392 — intervention group
Group type: EXPERIMENTAL
Intervention: Suicide attempters (n=22)
Number of subjects: 68
Study 31399392 — intervention group
Group type: COMPARATOR
Intervention: Ideating nonattempters (n=46)
Number of subjects: 68
Study 31399392 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral performance indices
Number of subjects: 68
Study 29884164 — intervention group
Group type: EXPERIMENTAL
Intervention: NIATx implementation strategies, including coaching and learning sessions over a 12‐month intervention period
Number of subjects: 50
Study 29884164 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study 26303195 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing fat intake from <25 to >35 %
Number of subjects: 1785
Study 26303195 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing carbohydrates intake from <45 to >60 %
Number of subjects: 1785
Study 26303195 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber intake >15 g/1000 kcal
Number of subjects: 1785
Study 26303195 — intervention group
Group type: EXPERIMENTAL
Intervention: Consumption of added sugars of >10 % of the energy intake
Number of subjects: 1785
Study 24746599 — intervention group
Group type: EXPERIMENTAL
Intervention: Transradial access
Number of subjects: 0
Study 24746599 — intervention group
Group type: EXPERIMENTAL
Intervention: Right transradial access
Number of subjects: 0
Study 24746599 — intervention group
Group type: EXPERIMENTAL
Intervention: Left transradial access
Number of subjects: 0
Study 24746599 — intervention group
Group type: COMPARATOR
Intervention: Transfemoral access
Number of subjects: 0
Study 22104345 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenofemoral ligation with stripping and multiple phlebectomies (group S)
Number of subjects: 73
Study 22104345 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided foam sclerotherapy (group F)
Number of subjects: 73
Study 22104345 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard surgery)
Number of subjects: 73
Study 20885315 — intervention group
Group type: EXPERIMENTAL
Intervention: Prompt coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI)
Number of subjects: 0
Study 20885315 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial strategy of PCI
Number of subjects: 0
Study 20885315 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG in patients with more extensive CAD
Number of subjects: 0
Study 20885315 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical therapy (OMT)
Number of subjects: 0
Study 18507656 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (5 mg intravenously)
Number of subjects: 12
Study 18507656 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine (administered at the time of the nadir)
Number of subjects: 12
Study 18507656 — intervention group
Group type: COMPARATOR
Intervention: Fingolimod (5 mg orally)
Number of subjects: 12
Study 16132406 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 0.1 mg subcutaneously 3 times/day for a total of 7 days
Number of subjects: 105
Study 16132406 — intervention group
Group type: COMPARATOR
Intervention: No octreotide
Number of subjects: 105
Study 11950022 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone administration of WOMAC LK3.0 Index
Number of subjects: 50
Study 11950022 — intervention group
Group type: COMPARATOR
Intervention: Onsite completion of WOMAC LK3.0 Index
Number of subjects: 50
Study 10225505 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavior Therapy (Trauma Treatment Protocol; TTP)
Number of subjects: 0
Study 10225505 — intervention group
Group type: COMPARATOR
Intervention: Eye Movement Desensitization and Reprocessing (EMDR)
Number of subjects: 0
Study 7549839 — intervention group
Group type: EXPERIMENTAL
Intervention: VAD (vincristine, doxorubicin, dexamethasone)
Number of subjects: 67
Study 7549839 — intervention group
Group type: EXPERIMENTAL
Intervention: MOD (mitozantrone, vincristine, dexamethasone)
Number of subjects: 67
Study 7549839 — intervention group
Group type: COMPARATOR
Intervention: Control (comparison between VAD and MOD)
Number of subjects: 67
Study 2084755 — intervention group
Group type: EXPERIMENTAL
Intervention: Form 1 of the Selective Reminding Test
Number of subjects: 90
Study 2084755 — intervention group
Group type: EXPERIMENTAL
Intervention: Form 2 of the Selective Reminding Test
Number of subjects: 90
Study 2084755 — intervention group
Group type: EXPERIMENTAL
Intervention: Form 3 of the Selective Reminding Test
Number of subjects: 90
Study 2084755 — intervention group
Group type: EXPERIMENTAL
Intervention: Form 4 of the Selective Reminding Test
Number of subjects: 90
Study 2084755 — intervention group
Group type: EXPERIMENTAL
Intervention: Form 5 of the Selective Reminding Test
Number of subjects: 90
Study 310917 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic digitalization with digoxin (1 or 1.5 mg before operation, 0.25 mg daily postoperatively)
Number of subjects: 140
Study 310917 — intervention group
Group type: COMPARATOR
Intervention: Untreated patients (control group)
Number of subjects: 140
Study 310917 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin dosage comparison (1 mg vs. 1.5 mg)
Number of subjects: 140
Study 31358243 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal massage (15-min video-guided training, performed twice a day for 4 weeks)
Number of subjects: 204
Study 31358243 — intervention group
Group type: COMPARATOR
Intervention: Standard approach of the clinic (control group)
Number of subjects: 204
Study 29354953 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist‐ankle needle therapy combined with patient controlled intravenous analgesia (PCIA)
Number of subjects: 98
Study 29354953 — intervention group
Group type: COMPARATOR
Intervention: Simple PCIA
Number of subjects: 98
Study 26164267 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic treatment (five different compounds)
Number of subjects: 2666
Study 23410138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX)
Number of subjects: 265
Study 21396901 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 valent pneumococcal conjugate vaccines (3 doses in infancy)
Number of subjects: 0
Study 21396901 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster dose at 9 months or early in the second year of life (suggested for evaluation)
Number of subjects: 0
Study 21396901 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving the vaccine)
Number of subjects: 0
Study 18312558 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy-restricted diet and exercise training
Number of subjects: 87
Study 18312558 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 87
Study 17634547 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg/d tibolone for 14 days
Number of subjects: 102
Study 17634547 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 14 days
Number of subjects: 102
Study 12605619 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia officinalis extract (60 drops/day)
Number of subjects: 42
Study 12605619 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 10863911 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen (50% mix)
Number of subjects: 87
Study 10863911 — intervention group
Group type: COMPARATOR
Intervention: Oxygen alone
Number of subjects: 87
Study 9184268 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant drugs
Number of subjects: 35
Study 9184268 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID
Number of subjects: 35
Study 9184268 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle relaxant drugs
Number of subjects: 35
Study 9184268 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesics
Number of subjects: 35
Study 1404819 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/d of tacrine
Number of subjects: 468
Study 1404819 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg/d of tacrine
Number of subjects: 468
Study 1404819 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg/d of tacrine
Number of subjects: 468
Study 1404819 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 468
Study 3932677 — intervention group
Group type: COMPARATOR
Intervention: 5 percent dextrose (Group I)
Number of subjects: 12
Study 3932677 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (Group II)
Number of subjects: 12
Study 30267257 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 30267257 — intervention group
Group type: COMPARATOR
Intervention: Pazopanib
Number of subjects: 0
Study 26497535 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 64
Study 26497535 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Therapy (MBT)
Number of subjects: 64
Study 26497535 — intervention group
Group type: COMPARATOR
Intervention: Control (no further treatment)
Number of subjects: 64
Study 24408114 — intervention group
Group type: EXPERIMENTAL
Intervention: Online hemodiafiltration (HDF)
Number of subjects: 342
Study 24408114 — intervention group
Group type: COMPARATOR
Intervention: Low-flux hemodialysis (HD)
Number of subjects: 342
Study 22387079 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump flow rate at 80% of theoretic value
Number of subjects: 30
Study 22387079 — intervention group
Group type: COMPARATOR
Intervention: Pump flow rate at 100% of theoretic value
Number of subjects: 30
Study 20140462 — intervention group
Group type: EXPERIMENTAL
Intervention: Landiolol (0.125 mg/kg)
Number of subjects: 14
Study 20140462 — intervention group
Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 14
Study 18621625 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (2 mg per day or 2.5 mg per day fixed dose for 5 of 7 days for 2 weeks)
Number of subjects: 80
Study 18621625 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 21 days)
Number of subjects: 80
Study 16060241 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral monitoring of blood flow velocity (BFV) in middle cerebral arteries using Multi Dop X; preoperative BWA on the affected side was 3.9 +/- 0.6 cm/s, intraoperative BWA increased to 7.7 +/- 1.1 cm/s (p < 0.05), postoperative BWA decreased to 4.2 +/- 0.8 cm/s.
Number of subjects: 12
Study 16060241 — intervention group
Group type: COMPARATOR
Intervention: Bilateral monitoring of blood flow velocity (BFV) in middle cerebral arteries using Multi Dop X; preoperative BWA on the affected side was 9.6 +/- 1.1 cm/s (p < 0.05), intraoperative BWA increased to 12.1 +/- 2.6 cm/s, postoperative BWA decreased to 10.4 +/- 2.9 cm/s.
Number of subjects: 12
Study 12445218 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) plus controlled-release chlorhexidine chip (CHX)
Number of subjects: 20
Study 12445218 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 20
Study 10461805 — intervention group
Group type: EXPERIMENTAL
Intervention: ISI of 8 s
Number of subjects: 75
Study 10461805 — intervention group
Group type: COMPARATOR
Intervention: ISI of 1 s
Number of subjects: 75
Study 10461805 — intervention group
Group type: COMPARATOR
Intervention: ISI of 5 s
Number of subjects: 75
Study 8765382 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 8765382 — intervention group
Group type: COMPARATOR
Intervention: Methohexital
Number of subjects: 50
Study 1752060 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) co-treatment
Number of subjects: 23
Study 1752060 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 1752060 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin treatment alone
Number of subjects: 23
Study 6126901 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 100
Study 6126901 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone (50 mg)
Number of subjects: 100
Study 6126901 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpromazine (50 mg)
Number of subjects: 100
Study 6126901 — intervention group
Group type: EXPERIMENTAL
Intervention: Melperone (10 mg)
Number of subjects: 100
Study 6126901 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (1 mg)
Number of subjects: 100
Study 30761502 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatible mapping of spoon tip defined as relevant
Number of subjects: 0
Study 30761502 — intervention group
Group type: EXPERIMENTAL
Intervention: Incompatible mapping of spoon handle defined as relevant
Number of subjects: 0
Study 30761502 — intervention group
Group type: EXPERIMENTAL
Intervention: Compatible mapping of chopstick handle defined as task relevant
Number of subjects: 0
Study 30761502 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional end of chopsticks defined as task relevant
Number of subjects: 0
Study 30761502 — intervention group
Group type: EXPERIMENTAL
Intervention: Colored red chopstick handles
Number of subjects: 0
Study 28658139 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical guide template (group I)
Number of subjects: 8
Study 28658139 — intervention group
Group type: COMPARATOR
Intervention: Free-hand operation (group II)
Number of subjects: 8
Study 27187097 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise program (AEP; n = 21)
Number of subjects: 65
Study 27187097 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance and aerobic program (RAP; n = 22)
Number of subjects: 65
Study 27187097 — intervention group
Group type: COMPARATOR
Intervention: Control (n = 22)
Number of subjects: 65
Study 24950987 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (500 mg)
Number of subjects: 450
Study 24950987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study 24950987 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 450
Study 22846686 — intervention group
Group type: EXPERIMENTAL
Intervention: Der p-SIT for 1 year
Number of subjects: 68
Study 22846686 — intervention group
Group type: COMPARATOR
Intervention: Control group (nonallergic controls)
Number of subjects: 68
Study 19321512 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Nurse Specialist (CNS) clinic
Number of subjects: 100
Study 19321512 — intervention group
Group type: COMPARATOR
Intervention: Traditional Junior Hospital Doctor (JHD) clinic
Number of subjects: 100
Study 17967673 — intervention group
Group type: EXPERIMENTAL
Intervention: LCT propofol 0.1 mg/kg before induction
Number of subjects: 200
Study 17967673 — intervention group
Group type: EXPERIMENTAL
Intervention: MCT/LCT propofol 0.1 mg/kg before induction
Number of subjects: 200
Study 17967673 — intervention group
Group type: COMPARATOR
Intervention: LCT control (normal saline plus Intralipid)
Number of subjects: 200
Study 17967673 — intervention group
Group type: COMPARATOR
Intervention: LCT/MCT control (normal saline plus Intralipid)
Number of subjects: 200
Study 15111341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate 20 mg once-daily for 96 weeks
Number of subjects: 435
Study 15111341 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ibandronate 50 mg once-daily for 96 weeks
Number of subjects: 435
Study 15111341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 435
Study 11136277 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide controlled ileal release (CIR) capsules, 9 mg orally in fasting state
Number of subjects: 8
Study 11136277 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide controlled ileal release (CIR) capsules, 9 mg orally after a heavy breakfast
Number of subjects: 8
Study 11136277 — intervention group
Group type: COMPARATOR
Intervention: Comparison of fasting vs postprandial conditions
Number of subjects: 8
Study 9488587 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg of oltipraz weekly for 8 weeks
Number of subjects: 234
Study 9488587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 234
Study 9488587 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg of oltipraz daily for 8 weeks
Number of subjects: 234
Study 7541355 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg flurbiprofen patch (n = 65)
Number of subjects: 131
Study 7541355 — intervention group
Group type: COMPARATOR
Intervention: Non‐medicated control (n = 66)
Number of subjects: 131
Study 3170993 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 1 mg twice daily
Number of subjects: 192
Study 3170993 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine 2 mg twice daily
Number of subjects: 192
Study 3170993 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 192
Study 30124572 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) (16 sessions)
Number of subjects: 247
Study 30124572 — intervention group
Group type: COMPARATOR
Intervention: Supportive‐expressive dynamic psychotherapy (SEDP) (18 sessions)
Number of subjects: 247
Study 28209175 — intervention group
Group type: EXPERIMENTAL
Intervention: Strataderm® topical silicone gel only
Number of subjects: 135
Study 28209175 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure garment therapy only
Number of subjects: 135
Study 28209175 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Strataderm® topical silicone gel and pressure garment therapy
Number of subjects: 135
Study 28209175 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 135
Study 25451487 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting + surgical ventricular reconstruction
Number of subjects: 1000
Study 25451487 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting alone
Number of subjects: 1000
Study 24119916 — intervention group
Group type: EXPERIMENTAL
Intervention: Insecticide-treated bed nets (ITN)
Number of subjects: 8175
Study 24119916 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ITN)
Number of subjects: 8175
Study 20442991 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous vertebroplasty (PV)
Number of subjects: 80
Study 18086218 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus F19 (LF19)
Number of subjects: 179
Study 18086218 — intervention group
Group type: COMPARATOR
Intervention: Control (no LF19)
Number of subjects: 179
Study 16814526 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Adaptations and Skills Training (FAST)
Number of subjects: 240
Study 16814526 — intervention group
Group type: COMPARATOR
Intervention: Attention-Control (AC)
Number of subjects: 240
Study 14517705 — intervention group
Group type: EXPERIMENTAL
Intervention: Noscapine (oral administration)
Number of subjects: 10
Study 14517705 — intervention group
Group type: COMPARATOR
Intervention: Control (no noscapine treatment)
Number of subjects: 10
Study 11377130 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous bis-glycinate chelate (5 mg of Fe daily per kg for 28 days)
Number of subjects: 40
Study 11377130 — intervention group
Group type: COMPARATOR
Intervention: FeSO4 (5 mg of Fe daily per kg for 28 days)
Number of subjects: 40
Study 9754192 — intervention group
Group type: EXPERIMENTAL
Intervention: Loteprednol etabonate (LE) 0.5%
Number of subjects: 203
Study 9754192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 203
Study 7826580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose-based membranes (regenerated cellulose and cellulose acetate)
Number of subjects: 0
Study 7826580 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic membranes (polysulfone and polyacrilonitrile)
Number of subjects: 0
Study 7826580 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose-based membranes
Number of subjects: 0
Study 7826580 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic membranes
Number of subjects: 0
Study 3073279 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% azelaic acid
Number of subjects: 60
Study 3073279 — intervention group
Group type: COMPARATOR
Intervention: 4% hydroquinone
Number of subjects: 60
Study 30732579 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparinoid moisturizer applied 2 weeks post-WBRT
Number of subjects: 76
Study 30732579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no moisturizer)
Number of subjects: 76
Study 30732579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylaxis group (moisturizer from the beginning of RT)
Number of subjects: 76
Study 28357554 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat ETV
Number of subjects: 81
Study 28357554 — intervention group
Group type: EXPERIMENTAL
Intervention: Shunt post-ETV
Number of subjects: 81
Study 28357554 — intervention group
Group type: COMPARATOR
Intervention: Primary shunt
Number of subjects: 81
Study 24974219 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic health warnings
Number of subjects: 0
Study 24974219 — intervention group
Group type: COMPARATOR
Intervention: Text-only warning statement
Number of subjects: 0
Study 22692120 — intervention group
Group type: EXPERIMENTAL
Intervention: Stable bench
Number of subjects: 16
Study 22692120 — intervention group
Group type: COMPARATOR
Intervention: Balance cushion
Number of subjects: 16
Study 22692120 — intervention group
Group type: COMPARATOR
Intervention: Swiss ball
Number of subjects: 16
Study 22692120 — intervention group
Group type: COMPARATOR
Intervention: Swiss ball compared to balance cushion
Number of subjects: 16
Study 22692120 — intervention group
Group type: COMPARATOR
Intervention: Stable bench compared to Swiss ball
Number of subjects: 16
Study 22017930 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 25
Study 22017930 — intervention group
Group type: EXPERIMENTAL
Intervention: Biolimus-eluting stents (BES)
Number of subjects: 25
Study 22017930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 25
Study 22017930 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-diabetic patients
Number of subjects: 25
Study 19567547 — intervention group
Group type: EXPERIMENTAL
Intervention: MPC
Number of subjects: 170
Study 16917623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 26